Two Sigma Advisers’s Exagen XGN Stock Holding History

Two Sigma Advisers’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-161,000	Closed	-$979K	–	2188
2025 Q4	$979K	Buy	161,000 +76,900	+91%	+$700K	﹤0.01%	1488
2025 Q3	$924K	Buy	+84,100	New	+$745K	﹤0.01%	1497

Other funds holding XGN

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

FCM

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

MBAM

Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return

Two Sigma Advisers's XGN Position: Q1 2026 in Review

Two Sigma Advisers sold out of Exagen (XGN) in Q1 2026, closing a stake of 161,000 shares — an estimated $979K sold.

Two Sigma Advisers first reported a position in XGN in Q3 2025 and held it in 2 quarters. The position peaked at $979K in Q4 2025. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.

Two Sigma Advisers reported no remaining Exagen position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 161,000 Exagen shares in Q1 2026, an estimated $979K.
Two Sigma Advisers first reported a position in Exagen in Q3 2025 and held it in 2 quarters.
Two Sigma Advisers's Exagen position peaked at $979K in Q4 2025.
61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.